Online inquiry

IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6944MR)

This product GTTS-WQ6944MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6944MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9942MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ5428MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ11231MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ6571MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ4925MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ2727MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ9831MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ5471MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDB-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW